Pantoprazol G.L. (Pantoprazole Sodium Sesquihydrate)

Pantoprazol G.L. is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining.
• Erosive oesophagitis: heals erosive lesions and prevents recurrence.
• Peptic ulcer disease (duodenal and gastric ulcers): accelerates ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the disorder.

• Pantoprazole binds selectively to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By irreversibly inhibiting this pump, it blocks the final step of acid production, leading to a sustained reduction in gastric acidity and allowing damaged mucosa to heal.

Pantoprazol G.L. may cause a range of adverse reactions. The frequency and severity vary among patients.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea: occasional and transient.
• Abdominal pain: mild discomfort.
• Flatulence: excess gas.
• Constipation: infrequent.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Clostridioides difficile infection: persistent watery diarrhoea.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Acute interstitial nephritis: kidney inflammation.
• Liver enzyme elevation: signs of hepatic stress.

When prescribing Pantoprazol G.L., clinicians should consider several safety aspects:

• Assess renal function: dose adjustment may be required in severe impairment.
• Review concomitant medications: potential for interaction with drugs that need an acidic environment.
• Monitor long‑term therapy: evaluate need for continued use after 8‑12 weeks.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Elderly patients: start with the lowest effective dose and monitor for fractures.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol G.L. can affect the pharmacokinetics of several co‑administered medicines. Awareness of these interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet activity, may increase cardiovascular risk.
• Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral effect.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, monitor coagulation parameters.
• Methotrexate: reduced clearance, watch for toxicity.
• Digoxin: higher serum levels, assess cardiac function.
• Iron supplements: diminished absorption, separate dosing by at least 2 hours.